KERSTEN WOODLEE: Open Payments
NPI 1154560555 · NASHVILLE, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,580 in 136 payments from 13 companies in 2025. Trend: 2023 $2,031 · 2024 $1,920 · 2025 $2,580
Food & beverage: $2,575Education: $5
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 20 | $460 |
| Janssen Pharmaceuticals, Inc | 22 | $372 |
| Teva Pharmaceuticals USA, Inc. | 19 | $344 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $325 |
| Neurocrine BioSciences, Inc. | 10 | $233 |
| E.R. Squibb & Sons, L.L.C. | 13 | $224 |
| ABBVIE INC. | 22 | $212 |
| Vanda Pharmaceuticals Inc. | 6 | $145 |
| Otsuka America Pharmaceutical, Inc. | 6 | $114 |
| Lundbeck LLC | 2 | $57 |
Products named: ARISTADA, INVEGA SUSTENNA, CAPLYTA, UZEDY, INGREZZA, COBENFY, VRAYLAR, REXULTI.
Industry payments across TN — which companies pay providers there.
